Search our Database of Scientific Publications and Authors

I’m looking for a

    44750 results match your criteria Psoriasis

    1 OF 895

    Guselkumab for the Treatment of Psoriasis.
    BioDrugs 2018 Feb 22. Epub 2018 Feb 22.
    Department of Dermatology, Centro Hospitalar do Porto, Porto, Portugal.
    Psoriasis is a common, chronic, immune-mediated, inflammatory skin disease with systemic involvement and significant impact on patients' quality of life. Several biologic treatments have been developed in recent decades, such as tumor necrosis factor (TNF)-α inhibitors, a non-selective interleukin (IL)-23 inhibitor (ustekinumab, which also inhibits IL-12), and-most recently-IL-17 inhibitors. Guselkumab is a novel biological therapy that selectively targets IL-23 and is the first-in-class selective IL-23 inhibitor approved to treat moderate-to-severe plaque psoriasis. Read More

    Prevalence and type II diabetes-associated factors in psoriatic arthritis.
    Clin Rheumatol 2018 Feb 22. Epub 2018 Feb 22.
    Rheumatology Division, Department of Internal Medicine, Hospital Universitario Central de Asturias (HUCA), Avenida de Roma s/n, 33011, Oviedo, Spain.
    Diabetes is a common cardiovascular risk factor in psoriatic arthritis (PsA). Although the prevalence of diabetes is high, the factors associated with it in PsA are poorly understood. We aimed to analyse the prevalence of type II diabetes and diabetes-associated factors in a hospital-based population with PsA. Read More

    Apremilast Alters Behavioral Responses to Ethanol in Mice: I. Reduced Ethanol Consumption and Preference.
    Alcohol Clin Exp Res 2018 Feb 22. Epub 2018 Feb 22.
    Waggoner Center for Alcohol and Addiction Research, The University of Texas at Austin, 78712.
    Background: Phosphodiesterase type 4 (PDE4) inhibitors produce widespread anti-inflammatory effects and reduce ethanol consumption in several rodent models. These drugs are potential treatments for several diseases, including central nervous system disorders, but clinical use is limited by their emetic activity. Apremilast is a selective PDE4 inhibitor with fewer gastrointestinal side effects that is FDA approved for the treatment of psoriasis. Read More

    Complete response of secukinumab in palmoplantar psoriasis.
    Dermatol Online J 2017 Oct 15;23(10). Epub 2017 Oct 15.
    Department of Dermatology, Hospital de Manacor, Islas Baleares, Spain. vrocamorad@ gmail.com.
    Palmoplantar psoriasis is plaque psoriasis involving the palms and soles. Palmoplantar psoriasis is a treatment challenge for dermatologists and it is difficult to treat with topical and systemic therapies. Owing to its location and manifestations, palmoplantar psoriasis is associated with greater pain, functional limitations, and significant impairment of health-related quality of life. Read More

    Pénfigo foliáceo agravado por fármacos en un paciente con psoriasis, con buena respuesta a adalimumab.
    Dermatol Online J 2017 Oct 15;23(10). Epub 2017 Oct 15.
    Servicio de Dermatología. Hospital Universitario Rey Juan Carlos. Móstoles. Madrid. España.
    El pénfigo foliáceo es una enfermedad autoinmune ampollosa debida a la producción de autoanticuerpos frente a la desmogleína 1. Presentamos el caso de un paciente con psoriasis y pénfigo foliáceo agravado por enalapril y amlodipino, con buena respuesta de ambas patologías a la terapia con adalimumab.Pemphigus foliaceus is a blistering autoimmune disease related to the production of autoantibodies against desmoglein 1. Read More

    Clinical improvement of a patient with both amyopathic dermatomyositis and psoriasis following treatment with cyclosporine.
    Dermatol Online J 2017 Aug 15;23(8). Epub 2017 Aug 15.
    Department of Dermatology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, California.
    Clinically amyopathic dermatomyositis (CADM) is an uncommon subtype of dermatomyositis that rarely presents simultaneously with psoriasis. There are subsequently few reports discussing the management of concurrent CADM and psoriasis. Furthermore, skin lesions of CADM are often recalcitrant to first line dermatomyositis interventions. Read More

    A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy.
    Dermatol Online J 2017 Aug 15;23(8). Epub 2017 Aug 15.
    Department of Dermatology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.
    Nivolumab, a monoclonal antibody against the programmed cell death protein 1 (PD-1), has shown promising results in patients with advanced malignancies, including melanoma, lung cancer, and renal cancer. Immune-related adverse events (irAEs) have been reported, including both organ-specific toxicities and skin toxicities. Herein, we report a case of predominantly palmoplantar psoriasis with severe nail involvement, psoriatic arthritis, and autoimmune hypothyroidism after receiving nivolumab treatment for lung cancer. Read More

    Mycobacterium marinum infection contracted from seaweed wrap in a psoriasis patient undergoing treatment with adalimumab.
    Dermatol Online J 2017 Aug 15;23(8). Epub 2017 Aug 15.
    Department of Dermatology, Galway University Hospital, Galway, Ireland.
    We report a patient with psoriasis who developed Mycobacterium marinum (M. marinum) infection after seven years of treatment with adalimumab, a human anti-TNF (tumor necrosis factor) monoclonal antibody. TNF is a pro-inflammatory cytokine that plays a central role in the pathogenesis of psoriasis and a number of other immune-mediated inflammatory diseases. Read More

    Treatment of selective antibody deficiency with IVIG resulting in decreased frequency of streptococcal infection and improvement of guttate psoriasis.
    Dermatol Online J 2017 Aug 15;23(8). Epub 2017 Aug 15.
    Department of Dermatology, Saint Louis University, Saint Louis, Missouri.
    Multiple endocrine neoplasia (MEN) type I, an autosomal dominant disorder caused by mutations in the MEN1 gene, is classically associated with parathyroid, pituitary, and pancreatic tumors. Patients with MEN type I also frequently exhibit multiple cutaneous lesions, specifically facial angiofibromas and collagenomas. Herein we describe a patient with genetically confirmed MEN type I syndrome who presented with trichodiscomas, skin tumors characteristic of Birt-Hogg-Dubé (BHD) syndrome. Read More

    Unique urticarial presentation of minocycline-induced lupus erythematosus.
    Dermatol Online J 2017 Aug 15;23(8). Epub 2017 Aug 15.
    Department of Dermatology, University of California, Davis, Sacramento, CA USA, Department of Biological Sciences, California State Univeristy, Sacramento, CA USA.
    The association between guttate psoriasis and infection with group A Streptococcus (GAS) has been well established in the medical literature. However, responses to treatments aimed at GAS eradication such as systemic antibiotics or tonsillectomy are inconsistent. Further complicating treatment recommendations for a disease with a suspected microbial trigger, the standard therapy for severe psoriasis is with systemic immunosuppressant medications. Read More

    Dermatologic manifestations of acromegaly: A case in point and a focused review.
    Dermatol Online J 2017 Aug 15;23(8). Epub 2017 Aug 15.
    Department of Dermatology, State University of New York Downstate Medical Center, Brooklyn, New York, Dermatology Service, Veterans Affairs Medical Center, Brooklyn, New York.
    Acromegaly is a systemic syndrome caused by overproduction of growth hormone. Cutaneous, endocrine, cardiovascular, skeletal, and respiratory systems are affected. Cutaneous changes in acromegaly relate to overexpression of growth hormone and insulin-like growth factor 1 on skin cells and adnexa. Read More

    Psoriasiform mycosis fungoides: a rare form of the disease with review of the literature.
    Dermatol Online J 2017 Sep 15;23(9). Epub 2017 Sep 15.
    Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
    Background: Mycosis fungoides (MF) typically presents as erythematous scaly patches or plaques that may progress to cutaneous tumors. Although MF may be presented like other dermatoses, initial presentation as psoriasiform plaques simulating psoriasis is rare. Differentiating MF from psoriasis is important because systemic therapies used for psoriasis can worsen MF. Read More

    Associated conditions in patients with multiple dermatofibromas: Case reports and literature review.
    Dermatol Online J 2017 Sep 22;23(9). Epub 2017 Sep 22.
    Department of Internal Medicine, Scripps Mercy Hospital, San Diego, California.
    Dermatofibromas are benign, fibrohistiocytic, dermal tumors. Solitary dermatofibromas may be incidental findings, whereas multiple dermatofibromas may be associated with systemic conditions or previous therapies. Two women and one man with multiple dermatofibromas and an associated systemic condition, immunosuppression, or both, are described. Read More

    Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
    Dermatol Online J 2017 Jul 15;23(7). Epub 2017 Jul 15.
    Marmara University School of Medicine, Department of Dermatology, Istanbul, Turkey.
    Janus kinase inhibitors are emerging treatment alternatives in various immune-mediated diseases including alopecia universalis. Herein, we report a patient with psoriasis and alopecia universalis in whom treatment with tofacitinib led to remission of psoriasis without improvement in alopecia universalis. Despite the promising potential in alopecia areata treatment, research evaluating the efficacy of different Janus kinase inhibitors and possible prognostic factors related with a more favorable response are warranted. Read More

    Adalimumab-related alopecia in a patient affected by psoriasis.
    Dermatol Online J 2017 Jul 15;23(7). Epub 2017 Jul 15.
    Department of Dermatology, Hospital Universitari Sagrat Cor, Barcelona, Spain.
    Alopecia induced by biological therapy is a rare side effect of this type of drugs. A total of 23 patients of psoriasiform eruptions with severe scalp involvement that induced alopecia during anti-tumor necrosis factor (anti-TNF) treatment of non-dermatological conditions have been previously reported. We present a 50-year-old man affected by plaque psoriasis that developed psoriasiform patches with alopecia over his scalp 10 months after initiating treatment with adalimumab. Read More

    The role of interleukin-17 in the pathogenesis of hidradenitis suppurativa.
    Dermatol Online J 2017 Jul 15;23(7). Epub 2017 Jul 15.
    Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.
    Hidradenitis suppurativa is a chronic inflammatory skin condition affecting primarily the axillary, perianal, and inguinal areas. Patients with hidradenitis suppurativa present with occlusion and subsequent rupture of follicular ducts, profound abscesses, fistulae, odorous discharge, fibrosis, and scar formation, causing significant morbidity. Knowledge of the pathogenesis of hidradenitis suppurativa is limited and treatment with antimicrobial drugs, immunosuppressants, and surgical procedures have shown varying results. Read More

    Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation.
    Recent Pat Anticancer Drug Discov 2018 Feb 19. Epub 2018 Feb 19.
    Group for Molecular Oncology, Institute for Medical Research, University of Belgrade, Dr. Subotica 4, 11129 Belgrade. Serbia.
    Background: IL-17A is a founding member of the IL-17 family that has been implicated in the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. In cancer, IL-17A participates in many key events for tumor development, in part by affecting innate and adaptive immune system and also by direct modulation of many pro-tumor events. Moreover, IL-17A dysregulation at the site of inflammation is associated with rheumatoid arthritis, multiple sclerosis, psoriasis, among others. Read More

    The Macrophage Mannose Receptor Regulate Mannan-Induced Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis-Like Disease Models.
    Front Immunol 2018 6;9:114. Epub 2018 Feb 6.
    Medicity Research Laboratory, University of Turku, Turku, Finland.
    The injection of mannan into mice can result in the development of psoriasis (Ps) and psoriatic arthritis (PsA), whereas co-injection with antibodies toward collagen type II leads to a chronic rheumatoid-like arthritis. The critical event in all these diseases is mannan-mediated activation of macrophages, causing more severe disease if the macrophages are deficient in neutrophil cytosolic factor 1 (Ncf1), i.e. Read More

    Can etanercept treatment failure in moderate-to-severe psoriasis be overcome by addition of low-dose methotrexate? - A single center experience.
    J Dermatolog Treat 2018 Feb 22:1-20. Epub 2018 Feb 22.
    a Department of Dermatology , Rabin Medical Center - Beilinson Hospital , Petach Tikva 4941492.
    Background: Loss of efficacy is a major anticipated shortcoming of utilizing etanercept and other biologic agents for treating moderate-to-severe psoriasis.

    Purpose: To investigate the addition of low-dose methotrexate as a means to increase etanercept drug survival.

    Methods: Eleven patients with severe psoriasis were switched to a combination of etanercept with low-dose methotrexate therapy, after a primary or secondary failure with etanercept treatment as a monotherapy. Read More

    OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States.
    J Cutan Med Surg 2018 Feb 1:1203475418755998. Epub 2018 Feb 1.
    6 Amgen Canada, Mississauga, ON, Canada.
    Background: OBSERVE-5 surveillance registry results evaluating etanercept safety and effectiveness in patients with moderate to severe psoriasis from Canada and the United States have been reported from data collected between May 2006 and December 2012. Although both countries have an identical indicated starting dose, the maintenance dose can differ and thus affect management strategies and outcomes.

    Objective: To compare the long-term safety and effectiveness outcomes of etanercept in the Canadian and US cohorts. Read More

    Association of Hidradenitis Suppurativa With Body Image.
    JAMA Dermatol 2018 Feb 21. Epub 2018 Feb 21.
    Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, University Hospital Charité, Berlin, Germany.
    Importance: Hidradenitis suppurativa (HS) leads to disfigurement and painful eruptions in terminal hair follicles of the intertriginous skin, mainly of axillary, genitofemoral, and perianal sites. It is associated with an excessive impairment of quality of life, psychiatric disorders, and sexual distress. Body image impairment has been linked to depression and anxiety and has been described for some dermatologic disorders but has not yet been investigated in patients with HS. Read More

    Demyelination during anti-tumour necrosis factor therapy for psoriasis.
    Clin Exp Dermatol 2018 Feb 21. Epub 2018 Feb 21.
    Department of Dermatology, St James's Hospital, Dublin, Ireland.
    Anti-tumour necrosis factor (anti-TNF) therapies have been associated with neurological complications, including in rare cases demyelinating disease. It is currently unknown whether patients who have received more than one immunosuppressive agent or anti-TNF have a greater risk of demyelination. We report the case of a 37-year-old woman with psoriasis who presented with an acute episode of demyelination while on anti-TNF therapy. Read More

    Cutaneous Manifestations of Reactions to Biologics.
    Curr Allergy Asthma Rep 2018 Feb 21;18(2):12. Epub 2018 Feb 21.
    Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.
    Purpose Of Review: The goal of this paper is to review the major adverse cutaneous reactions that have been reported to the most commonly used biologics.

    Recent Findings: Anti-TNF agents and immune checkpoint inhibitors have significant, immune-mediated cutaneous manifestations that can necessitate discontinuation. Anti-TNF agents, IL-6 inhibitors, and IL-12/23 inhibitors can paradoxically cause psoriasis flares or unmask previously undiagnosed psoriasis. Read More

    Erythrodermic Psoriasis in a Man with Monoclonal B-cell Lymphocytosis.
    Cureus 2017 Dec 11;9(12):e1936. Epub 2017 Dec 11.
    Department of Dermatology, University of California, San Diego.
    Erythroderma is characterized by erythema involving greater than 90% of the body surface area and may be caused by several etiologies, including erythrodermic psoriasis. Psoriasis is an autoimmune skin and systemic condition characterized by erythematous and scaly plaques. Monoclonal B-cell lymphocytosis is an asymptomatic hematological disorder diagnosed by elevated, small, clonal B-cell counts in the peripheral blood. Read More

    TRAF6 regulates EGF-induced cell transformation and cSCC malignant phenotype through CD147/EGFR.
    Oncogenesis 2018 Feb 20;7(2):17. Epub 2018 Feb 20.
    The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
    TRAF6, a well-known adapter molecule, plays pivotal role in TLR/IL-1R associated signaling pathway. Although TRAF6 has been shown to have oncogenic activity in various malignant tumors, the details remain unclear. In this study, we demonstrated that TRAF6 facilitates Ras (G12V) and EGF-induced cellular transformation through EGFR. Read More

    Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
    J Drugs Dermatol 2018 Feb;17(2):221-228

    BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated efficacy and safety in systemic-naive patients with chronic moderate plaque psoriasis with lower psoriasis-involved body surface area (BSA; 5%-10%) during the 16-week, double-blind, placebo-controlled phase. We describe efficacy and safety of apremilast in this population through week 52 in UNVEIL. Read More


    Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical Trials.
    J Drugs Dermatol 2018 Feb;17(2):200-206

    BACKGROUND: Injection-site reactions (ISRs) are reported with biologic therapies. The objective of this study was to comprehensively characterize ISRs among moderate-to-severe psoriasis patients treated with ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A.

    METHODS: ISRs are presented from UNCOVER-1, UNCOVER-2, and UNCOVER-3 (12 weeks) and all ixekizumab-exposed patients in 11 controlled and uncontrolled trials (156 weeks). Read More


    Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis.
    J Drugs Dermatol 2018 Feb;17(2):187-194
    Importance: While psoriasis (Ps) is mainly characterized as an adult disease, it can also develop during childhood. However, prevalence estimates of pediatric psoriasis in the United States (US) are lacking.

    Objective: To assess the 2015 annual prevalence of Ps and moderate-to-severe Ps in pediatric individuals in the US. Read More

    Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis.
    J Drugs Dermatol 2018 Feb;17(2):180-186
    Background: Psoriasis (Ps) is a chronic inflammatory immune-mediated skin disease that has been identified as a risk factor for various conditions including neoplasms.

    Objective: To compare prevalence of cancer between Ps and Ps-free patients.

    Methods: Adult patients continuously enrolled for ≥12 months (≥1 month in 2014) were selected from a large United States (US) claims database (Q1:2010-Q4:2014) and classified as Ps patients (≥2 Ps diagnoses; International Classification of Diseases 9th Revision, [ICD-9] code: 696. Read More

    Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis.
    Scand J Rheumatol 2018 Feb 20:1-6. Epub 2018 Feb 20.
    g Novartis Pharma AG , Basel , Switzerland.
    Objective: To assess the efficacy and safety of secukinumab in patients with rheumatoid arthritis (RA) who failed to respond to tumour necrosis factor- α (TNF-α) inhibitors.

    Method: This phase III double-blind, double-dummy, placebo-controlled study (NCT01770379) randomized (1:1:1) patients to subcutaneous secukinumab 150 mg, secukinumab 75 mg, or placebo at baseline, weeks 1, 2, 3, and 4, and then every 4 weeks. American College of Rheumatology (ACR) 20 response at week 24 was the primary endpoint. Read More

    Incidence of Autoimmune and Related Disorders After Resolution of Endogenous Cushing Syndrome in Children.
    Horm Metab Res 2018 Feb 19. Epub 2018 Feb 19.
    Section on Endocrinology and Genetics, Eunice Kennedy Shriver Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland, USA.
    Glucocorticoids are widely used for immunosuppression in autoimmune diseases. After the resolution of hypercortisolemia, the immune system recovers allowing for autoimmune diseases to manifest. Here we investigated the presence of autoimmune and related diseases that developed after cure of endogenous Cushing syndrome (CS) in children. Read More

    Major role for TRPV1 and InsP3R in PAR-2-elicited inflammatory mediator production in differentiated human keratinocytes.
    J Invest Dermatol 2018 Feb 16. Epub 2018 Feb 16.
    University of Western Brittany, Laboratory Interaction Neurons-Keratinocytes (LINK), EA4685, Brest, France. Electronic address:
    Proteinase-activated receptor-2 (PAR-2) activation in basal keratinocytes stimulates inflammation via the Ca-dependent production of mediators such as interleukin (IL)-1β, tumor necrosis factor (TNF)-α and thymic stromal lymphopoietin (TSLP). In this study, we investigated PAR-2 calcium signaling and the consequent production of inflammatory mediators in differentiated human primary keratinocytes (DhPKs). Stimulation with the PAR-2 activating peptide SLIGKV promoted Castore depletion in both undifferentiated human primary keratinocytes (UhPKs) and DhPKs. Read More

    Handheld reflectance confocal microscopy, dermatoscopy and histopathological correlation of common inflammatory balanitis.
    Skin Res Technol 2018 Feb 18. Epub 2018 Feb 18.
    Dermatology Clinic, University of Catania, Catania, Italy.
    Background: The term balanitis includes a variety of inflammatory skin diseases involving the glans penis whose clinical diagnosis may be challenging. A biopsy is often required to obtain a definitive diagnosis, although it is barely accepted by patients. Reflectance confocal microscopy (RCM), that provides a real-time, en face imaging of the epidermis and upper dermis, is currently utilized for the diagnosis of some neoplastic and inflammatory skin diseases. Read More

    Childhood trauma and resilience in psoriatic patients: A preliminary report.
    J Psychosom Res 2018 Mar 8;106:25-28. Epub 2018 Jan 8.
    Institute of Psychiatry and Psychology, Fondazione Policlinico Universitario "A. Gemelli", Università Cattolica del Sacro Cuore, Rome, Italy.
    Aims: Psoriasis is a chronic inflammatory skin disease with a complex etiology, involving the immune system, genetic factors, and external/internal triggers, with psychosomatic aspects. The aim of the study was to investigate childhood trauma and resilience in a psoriatic sample compared with healthy controls. Correlations between childhood trauma, resilience, quality of life, clinical data and psoriatic features were also evaluated. Read More

    Rates of latent tuberculosis infection in patients treated with TNF inhibitors for psoriasis: a retrospective chart review.
    J Dermatolog Treat 2018 Feb 19:1-17. Epub 2018 Feb 19.
    c Kaiser Permanente Los Angeles Medical Center, Department of Dermatology , Los Angeles , CA.
    Background Although tuberculosis screening guidelines for psoriasis patients on TNF inhibitors exist, few studies have reported the prevalence of latent tuberculosis infection (LTBI) and conversion rates in this population. Objective To determine the incidence of LTBI and active tuberculosis in patients with psoriasis receiving TNF inhibitor therapy. Methods A total of 138 patients were included in our retrospective study of patients treated from September 2004 to September 2017. Read More

    IL12B, IL23A, IL23R and HLA-C*06 genetic variants in psoriasis susceptibility and response to treatment.
    Hum Immunol 2018 Feb 15. Epub 2018 Feb 15.
    Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, Szczecin, Poland. Electronic address:
    The role of interleukin-23 is crucial in the pathogenesis of psoriasis, and IL23A, IL12B and IL23R genetic variants have been associated with the disease in genome-wide association studies. In the current paper we have conducted a confirmation study of the abovementioned genetic factors in a case-control analysis of 507 psoriatic patients and 396 controls from a Polish population, and subsequently analyzed the impact of genetic variants on response to topical and NB-UVB therapy in a subset of 306 patients. Case-control analysis revealed an association of IL12B rs3212227 and IL23R rs11209026 minor allele carrier status with reduced odds for psoriasis (OR = 0. Read More

    Bioactive Lipid Mediators Profiles In Human Psoriasis Skin And Blood.
    J Invest Dermatol 2018 Feb 15. Epub 2018 Feb 15.
    Section of Inflammation and Cardiometabolic Disease, Cardio-Pulmonary Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD. Electronic address:
    Psoriasis (PSO) is a chronic immune-mediated disease that represents a unique model for investigating inflammation at local and systemic levels. Bioactive lipid mediators (LM) are potent compounds reported to play a role in the development and resolution of inflammation. Currently, it is not known to what extent these LM are involved in PSO pathophysiology and related metabolic dysfunction. Read More

    Frequency of Electrocardiographic Abnormalities in Patients With Psoriasis.
    Am J Cardiol 2018 Jan 31. Epub 2018 Jan 31.
    Laboratory of Experimental Cardiology, Department of Biomedical Sciences, Panum Institute, Copenhagen N, Denmark.
    Psoriasis is a chronic inflammatory disease associated with cardiovascular disease, for example, myocardial infarction, stroke, cardiovascular death, and arrhythmias. The resting electrocardiogram may carry prognostic information, but limited evidence is available of electrocardiographic findings in subjects with psoriasis. The electrocardiographic results were compared between 1,131 subjects with self-reported psoriasis and 18,397 controls participating in the Danish General Suburban Population Study (GESUS). Read More

    Diarylheptanoid from rhizomes of Curcuma kwangsiensis (DCK) inhibited imiquimod-induced dendritic cells activation and Th1/Th17 differentiation.
    Int Immunopharmacol 2018 Feb 14;56:339-348. Epub 2018 Feb 14.
    The Second Clinical School of Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510120, China. Electronic address:
    Background And Object: Dendritic cells (DCs) are critical for initiating the activation and differentiation of T cells in inflammatory diseases including psoriasis. Curcuma kwangsiensis S.G. Read More

    Author Correction to: Psoriasis in Skin of Color: Insights into the Epidemiology, Clinical Presentation, Genetics, Quality-of-Life Impact, and Treatment of Psoriasis in Non-White Racial/Ethnic Groups.
    Am J Clin Dermatol 2018 Feb 16. Epub 2018 Feb 16.
    Mount Sinai St. Luke's, 1090 Amsterdam Avenue, Suite 11B, New York, NY, 10025, USA.
    In the original publication, section 5, paragraph 1 was incorrectly published. Read More

    MicroRNA signature of regulatory T cells in health and autoimmunity.
    Biomed Pharmacother 2018 Feb 13;100:316-323. Epub 2018 Feb 13.
    Department of Immunology, School of Medicine, Babol University of Medical Sciences, Babol, Iran. Electronic address:
    MicroRNAs (miRNAs) are small RNA molecules with regulatory functions on the expression of genes through binding directly to target messenger RNA (mRNA) transcripts, eventuating in gene expression suppression via translational hindrance and/or target mRNA cleavage. These molecules have been established to participate in numerous critical cellular settings, including differentiation, development, and function of immune cells. As an important suppressor cell of immune system, regulatory T cells (Tregs) are important in modulating the immune homeostasis as well as tolerance to self-antigens. Read More

    Assessing the Importance of Treatment Goals in Patients with Psoriasis: Analytic Hierarchy Process vs. Likert Scales.
    Patient 2018 Feb 15. Epub 2018 Feb 15.
    Institute for Health Services Research in Dermatology and Nursing (IVDP), German Center for Health Services Research in Dermatology (CVderm), University Medical Center Hamburg-Eppendorf (UKE), Martinistraße 52, 20246, Hamburg, Germany.
    Background: To define treatment benefit, the Patient Benefit Index contains a weighting of patient-relevant treatment goals using the Patient Needs Questionnaire, which includes a 5-point Likert scale ranging from 0 ("not important at all") to 4 ("very important"). These treatment goals have been assigned to five health dimensions. The importance of each dimension can be derived by averaging the importance ratings on the Likert scales of associated treatment goals. Read More

    1 OF 895